Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
GigaMune logo — company profile

GigaMune

Founded 2017 United States San Francisco, United States 14 employees Seed Total: $300.00K Biotechnology

General Information

Company Name GigaMune
Founded Year 2017
Location United States San Francisco, United States +1
Employees 14
Industries Biotechnology
Funding Stage Seed
Social

Get notified when GigaMune moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About GigaMune

GigaMune is a biotechnology startup founded in 2017 and headquartered in the United States. The company is focused on developing a groundbreaking technology for in vivo, T cell targeted gene delivery of T cell receptors (TCRs) and chimeric antigen receptors (CARs) to combat serious diseases such as cancer and autoimmune diseases. GigaMune aims to revolutionize the conventional ex vivo cell therapy manufacturing, with the primary objectives of cost reduction and improved patient outcomes. The company's achievements include the development of a high throughput immune screening technology, which was highlighted in Nature Biotechnology (DOI: 10.1038/s41587-020-0438-y), along with a petabase-scale protein search algorithm featured in Nature (DOI: 10.1038/s41586-021-04332-2). This demonstrates their commitment to cutting-edge research and innovative solutions in the biotechnology sector. GigaMune recently secured Seed Round investment on 10 March 2023, indicating increased investor interest and confidence in the company's potential. As a venture capital investor, GigaMune presents an intriguing opportunity in the biotechnology space, with its disruptive technology and ambitious vision to deliver any gene to any cell in any tissue location at any time.

Taxonomy: therapeutics, gene delivery, T cell receptor, chimeric antigen receptor, cancer therapy, autoimmune disease, immunotherapy, cell therapy, high throughput screening, protein search algorithm

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• - 10 Mar 2023
Seed Round •••••• 3
Investor Investor
•••• •••• 		01 Nov 2022
Angel Round •••••• - 01 May 2019
Grant •••••• 1 •••• •••• 01 Sep 2018

GigaMune Alternatives & Competitors

GigaMune vs
Tmunity Therapeutics
Tmunity Therapeutics

Pioneering the future of immunotherapy through innovative T cell engineering to tackle a diverse arr...

Acquired
12 employees
Biotechnology, Health Care
GigaMune vs
Sana Biotechnology, Inc.
Sana Biotechnology, Inc. United States

Focused on creating and delivering engineered cells as medicines for patients

IPO
257 employees
Biotechnology, Health Care
GigaMune vs
Nanocell Therapeutics
Nanocell Therapeutics The Netherlands

Transforming cell & gene therapy

13 employees
Biotechnology

FAQ About GigaMune

GigaMune is a therapeutics company developing a novel technology for in vivo, T cell targeted gene delivery of T cell receptors (TCRs) and chimeric antigen receptors (CARs) for serious diseases such as cancer and autoimmune diseases. Our initial goal is to challenge conventional ex vivo cell therapy...
GigaMune was founded in 2017.
GigaMune is headquartered in San Francisco, United States.
GigaMune operates in the following industries: Biotechnology.
GigaMune has approximately 14 employees.
GigaMune has completed 4 funding rounds, raising a total of $300.00K. The latest funding stage is Seed.
Top alternatives and competitors to GigaMune include Tmunity Therapeutics, Sana Biotechnology, Inc., Nanocell Therapeutics, Basilard BioTech, Inc., iCell Gene Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GigaMune and Tmunity Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors GigaMune and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy